Background
==========

Chondrosarcoma (CHS) is a heterogeneous group of malignant tumors consisting of proliferating cartilaginous tissue; it is the second most common primary bone sarcoma after osteosarcoma. CHS constitutes 30% of all primary bone sarcomas. Because neither radiation therapy nor chemotherapy are effective against chondrosarcoma, wide resection with adequate surgical margins is the mainstay of primary treatment \[[@b1-medscimonit-25-10136]\]. According to previous studies, 8--38% of chondrosarcoma patients developed distant metastasis \[[@b2-medscimonit-25-10136]--[@b6-medscimonit-25-10136]\]. This has been confirmed to be an independent prognostic factor correlated with poor prognosis of chondrosarcoma patients \[[@b2-medscimonit-25-10136],[@b4-medscimonit-25-10136],[@b7-medscimonit-25-10136]--[@b11-medscimonit-25-10136]\]. Additionally, a majority of the distant metastatic sites were in the lungs \[[@b12-medscimonit-25-10136],[@b13-medscimonit-25-10136]\]. A systemic review revealed that sarcoma's pulmonary metastasis rate was about 18--50% \[[@b14-medscimonit-25-10136]\]. The development of pulmonary metastasis is a predictor of worse prognosis in CHS patients. The overall survival rate at 10 years by Kaplan-Meier analysis was 17% for patients who developed pulmonary metastasis, with a metastatic rate of approximately 9.6% \[[@b9-medscimonit-25-10136]\]. Nakamura et al. recently reported that the incidence of pulmonary metastasis in chondrosarcoma patients was 11.2%, and among patients with pulmonary metastasis, the overall survival at 3 years and 5 years was 51.5% and 45.7%, respectively \[[@b15-medscimonit-25-10136]\]. Early studies reported that older age, tumor site, higher grade of malignancies, and a larger tumor size are established risk factors for distant metastasis in chondrosarcoma patients. Other clinical characteristics have also been found as prognostic factors significantly associated with survival of chondrosarcoma patients, such as age, sex, year of diagnosis, tumor stage, tumor grade, tumor site, tumor size, surgery, and radiation \[[@b8-medscimonit-25-10136],[@b10-medscimonit-25-10136],[@b16-medscimonit-25-10136],[@b17-medscimonit-25-10136]\]. However, risk factors and prognostic factors for chondrosarcoma patients with pulmonary metastasis remain unclear. Therefore, it is necessary to identify risk factors for the incidence and prognosis in chondrosarcoma patients with pulmonary metastasis.

The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute is a comprehensive source of population-based information on cancer incidence and survival in the United States that was collected from 18 population-based cancer registries covering approximately 27.8% of the U.S. population. We utilized this open database to collect the information of demographic and clinical characteristics to investigate the association of risk factors with the incidence and prognosis in CHS patients with pulmonary metastasis (PM) at initial diagnosis.

Material and Methods
====================

Patient selection
-----------------

Patient data were abstracted from Incidence-SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975--2016 varying) using SEER\*Stat 8.3.5 software, which collects patients' demographic and clinical characteristics. Since the complete information on distant metastases was not available before 2010, we restricted our study to the period time between 2010 and 2016. The inclusion criteria were as follows: (1) chondrosarcoma patients diagnosed between 2010 and 2016; (2) histologic subtype limited to Chondrosarcoma (9220), Juxtacortical chondrosarcoma (9221), Myxoid chondrosarcoma (9231), Mesenchymal chondrosarcoma (9240), Clear cell chondrosarcoma (9242), Dedifferentiated chondrosarcoma (9243) according to the International Classification of Diseases for Oncology, 3rd Edition codes; (3) tumor sites limited to extremity (C40.0--C40.3), spine (C41.2), thoracic cage (C41.3), others included pelvic bones, sacrum, coccyx and associated joints (C41.4); (4) known survival time, complete follow-up. The exclusion criteria were as follows: (1) diagnosed at autopsy or via death certificate; (2) survival time code 0 months; (3) more than 1 primary tumor; (4) unknown primary tumor surgery information; (5) unknown sequence between radiation and surgery; (6) regional lymph nodes metastasis incomplete information; (7) unknown regional lymph nodes metastasis removed.

As shown in the flow chart ([Figure 1](#f1-medscimonit-25-10136){ref-type="fig"}), 1365 patients diagnosed with CHS from January 1, 2010, to December 31, 2016, were initially identified. After the exclusion of 351 ineligible patients, a total of 1014 patients remained, both with and without PM. Among those, data on 69 PM patients were collected to analyze the prognostic factors of overall survival for CHS with PM. Eventually, 1 patient who was dead from other causes was excluded, leaving 68 PM patients to predict the prognostic factors of cancer-specific survival.

Demographics and clinical characteristics
-----------------------------------------

Patients' demographics included age at diagnosis, sex, race, insurance status, and marital status. Marital status was characterized as unmarried or married. Unmarried included single (never married), widowed, divorced, separated, and unmarried or domestic partner. Clinical characteristics included tumor site, histologic subtype, tumor grade, Enneking staging, the presence or absence of regional lymph nodes metastases, local recurrence and pulmonary metastasis, tumor size, primary tumor surgery, regional lymph nodes removed, chemotherapy, radiation therapy and radiation sequence with surgery to investigate which characteristics are risk and prognostics factors for CHS with PM Primary site was classified as extremity (C40.0--C40.3), spine (C41.2), thoracic cage (C41.3), others included pelvic bones, sacrum, coccyx, and associated joints (C41.4). Histologic subtype was classified as conventional subtype (chondrosarcoma and juxtacortical), myxoid subtype, mesenchymal subtype, clear cell subtype, and dedifferentiated subtype. Regarding tumor grade, Grade I well-differentiated and grade II moderately differentiated lesions (ICD-O-3) were regrouped as low grade, whereas grade III poorly differentiated and grade IV undifferentiated and anaplastic lesions (ICD-O-3) were regrouped as high grade \[[@b4-medscimonit-25-10136],[@b18-medscimonit-25-10136]\]. According to Enneking staging system, tumor extension was divided into 2 groups: intracompartmental (A) and extracompartmental (B) \[[@b19-medscimonit-25-10136]\]. Chemotherapy and radiation therapy were referred to as the treatment for the primary tumor site. X-tile 3.6.1 software (Yale University, New Haven, Connecticut, USA) was employed to identify the optimal cutoff values for continuous variables such as age at diagnosis and tumor size. The optimal cutoff values for age at diagnosis was 67 years old, then age at diagnosis was stratified as younger age ≤67 years old and older age \>67 years old. The optimal cutoff values for tumor size was 8.6 cm and 15 cm. Tumor size was categorized as small size (≤8.6 cm), medium size (\>8.6--15 cm), and large size (\>15 cm) ([Figure 2](#f2-medscimonit-25-10136){ref-type="fig"}).

Statistical analysis
--------------------

A chi-square test was used to evaluate the differences between groups for categorical variables. The primary endpoint in this study included overall survival (OS) and CHS cancer-specific survival (CSS). OS was defined as the time interval from the date of diagnosis till the date of death due to any cause. CSS was defined as the time from diagnosis until death due to CHS. Univariate logistic regression was used to determine risk factors for CHS patients with PM. Those characteristics with P-values less than 0.05 in the univariate logistic regression analysis were continually chosen for the multivariate logistic analysis. The odds ratio (OR) and corresponding 95% confidence interval (CI) were used to show the association between clinical characteristics and PM development. Univariate and multivariate Cox proportional hazard models were applied to determine the independent predictors association among several variables for OS and CSS. The hazard ratios (HR) and corresponding 95% confidence interval (CI) were used to show the impact of patient factors on OS and CSS. All statistical analyses were performed using SPSS 22.0 (IBM Corporation, Armonk, NY, USA). Two-tailed and P-values less than 0.05 were considered statistically significant in all statistical tests.

Results
=======

Demographics and baseline characteristics for CHS patients diagnosed with PM
----------------------------------------------------------------------------

One thousand and fourteen patients diagnosed as CHS between 2010 and 2016 were collected from the SEER database. The overall cohort was mostly white patients (86%). The sex distribution demonstrated a slight male predominance (56.3%). The mean age for these patients was 52.68 ±17.64 years. Conventional subtype constituted approximately 81.9% of all histologic type chondrosarcomas. Among these CHS patients, 69 patients with PM were retrieved and the mean age of PM patients was 59.54±14.91 years. With regard to tumor primary site, patients with PM were, in ascending order: thoracic cage (5.3%); extremities (6.7%); spine (7%); pelvis, sacrum, coccyx (8.5%). In all histologic subtypes, the dedifferentiated subtype had the highest PM rate of 22.5%. The incidence rate of PM with high-grade tumor and low-grade tumor was 16.9% and 3.1%, respectively. Approximately 87.8% of CHS patients underwent surgery at the primary site, 9.4% had radiation therapy, and 11.9% had chemotherapy. Patients with PM received less primary site surgery and more chemotherapy and radiation therapy. The baseline of demographics and clinical characteristics of patients is presented in [Table 1](#t1-medscimonit-25-10136){ref-type="table"}.

The incidence of PM
-------------------

Sixty-nine CHS patients were diagnosed with PM, which accounted for 6.8% (69/1014) of the entire cohort. Based on the chi-squared test, as shown in [Table 1](#t1-medscimonit-25-10136){ref-type="table"}, the PM incidence of those patients with dedifferentiated subtype (χ^2^=49.181, P\<0.001), high grade of tumor malignancy (χ^2^=51.947, P\<0.001), extracompartmental tumor (χ^2^=20.941, P\<0.001), presence of regional lymph nodes metastases (LNM) (χ^2^=44.828, P\<0.001), presence of local recurrence (χ^2^=87.909, P\<0.001), large tumor size (χ^2^=32.863, P\<0.001), and married (χ^2^=9.640, P=0.008) were all significantly higher than their counterparts in each group.

Risk factors for developing pulmonary metastasis
------------------------------------------------

Univariate logistic regression analysis showed that factors positively associated with PM development at initial diagnosis included: dedifferentiated subtype (OR=5.896, 95% CI: 3.404--10.212, P\<0.001); high grade of tumor malignancy (OR=6.450, 95% CI: 3.673--11.328, P\<0.001); extracompartmental tumor (OR=4.970, 95% CI: 2.181--11.324, P\<0.001) presence of regional LNM (OR=13.820, 95% CI: 4.497--42.472, P\<0.001); presence of local recurrence (OR=28.678, 95% CI: 1.394--4.778, P=0.003); medium tumor size \>8.6--15 cm (OR=2.581, 95% CI: 2.013--6.977, P\<0.001), large tumor size \>15 cm (OR=4.267, 95% CI: 2.182--8.342, P\<0.001) and were married (OR=1.998, 95% CI: 1.157--3.449, P=0.013).

As demonstrated in [Table 2](#t2-medscimonit-25-10136){ref-type="table"}, multivariate logistic regression indicated that factors positively associated with higher risk of PM development at initial diagnosis included: dedifferentiated subtype (OR=2.207, 95% CI: 1.058--4.603, P=0.035); high grade of tumor malignancy (OR=2.946, 95% CI: 1.415--6.136, P=0.004); extracompartmental tumor (OR=2.783, 95% CI: 1.149--6.743, P=0.023); presence of regional LNM (OR=7.727, 95% CI: 2.117--28.210, P=0.002); presence of local recurrence (OR=22.699, 95% CI: 5.558--92.696, P\<0.001), large tumor size \>15 cm (OR=2.259, 95% CI: 1.044--4.884, P=0.038), and were married (OR=2.072, 95% CI: 1.115--3.853, P=0.021);

Prognostic factors for chondrosarcoma patients
----------------------------------------------

Because the survival rate of CHS patients is over 50%, the median overall survival time could not be calculated by Kaplan-Meier. Univariate and multivariate Cox regression analysis were conducted to determine those clinical characteristics which were associated with the prognosis of CHS patients. We found that male sex (P=0.001), older age (P\<0.001), dedifferentiated subtype (P\<0.001), high grade of tumor malignancy (P=0.041), extracompartmental tumor (P=0.016), presence of PM (P\<0.001), presence of local recurrence (P=0.002), and large tumor size (P=0.001) were associated with poor prognosis of OS. Details of the prognostic factors for CHS patients are listed in [Table 3](#t3-medscimonit-25-10136){ref-type="table"}. Remarkably, patients with pulmonary metastasis had worse prognosis than those without PM ([Figure 3](#f3-medscimonit-25-10136){ref-type="fig"}). Chemotherapy and radiation therapy were not statistically significant associated with prognosis. Resection (P\<0.001) and amputation (P=0.026) of the primary tumor were the only prognostic factors that were associated with a better prognosis compared to those without surgery.

Prognostic factors for patients with pulmonary metastasis
---------------------------------------------------------

The median overall survival time for CHS patients with PM was 7 months, while the median survival of the cohort was 29 months. At the end of the follow-up, 55 patients with PM (79.71%) had died, of whom 54 died of cancer. The prognostic factors for PM patients are shown in [Tables 4](#t4-medscimonit-25-10136){ref-type="table"} and [5](#t5-medscimonit-25-10136){ref-type="table"}. In the univariate analysis model, factors including older age (HR=2.364, 95% CI: 1.305--4.281, P=0.005); clear cell chondrosarcoma (CCC) subtype (HR=10.437, 95% CI: 1.275--85.470, P=0.029), and large tumor size (HR=2.331, 95% CI: 1.110--4.895, P=0.025) were all associated with poor prognosis of OS and CSS. In contrast, resection of the primary tumor had improved OS and CSS for PM patients ([Figure 4](#f4-medscimonit-25-10136){ref-type="fig"}). There was no significant impact on OS and CSS by the histological grade of the pulmonary metastasis. Multivariate Cox regression analysis revealed patients with older age (HR=2.668, 95% CI: 1.371--5.192, P=0.004), CCC subtype (HR=10.971, 95% CI: 1.216--98.942, P=0.033), and large tumor size (HR=4.613, 95% CI: 1.857--11.462, P=0.033) were associated with poor prognosis of OS and CSS for PM patients. Moreover, resection of the primary tumor tended to be another prognostic factor which could prolong OS and CSS in PM patients.

In this study, the homogeneous risk factor for the incidence and prognosis of CHS patients with PM was a large tumor size (\>15 cm). Patients with dedifferentiated subtype, high grade of malignancy, extracompartmental tumor, presence of regional LNM, presence of local recurrence, and whom were married were significantly associated with high risk of developing PM; however, they were not associated with OS and CSS of PM. Older patients and patients with CCC subtype were significantly correlated with poor prognosis of OS and CSS, but these factors could not predict the risk of developing PM ([Figure 5](#f5-medscimonit-25-10136){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, this is the first study using the Surveillance, Epidemiology, and End Results (SEER) database to investigate the risk factors and prognostic factors of CHS patients with PM. According to our findings, 6.8% of CHS patients presented with PM at initial diagnosis. This incidence rate is lower than the rate of 9.6--11.2% previously published \[[@b9-medscimonit-25-10136],[@b15-medscimonit-25-10136]\]. In the SEER database, asymptomatic patients are unable to be captured, which might have resulted in underestimation of PM incidence.

Due to the poor prognosis of CHS patients with PM, it is meaningful to determine factors that can identify the clinical characteristics of CHS patients who are at high risk of developing PM. As shown in our study, patients with dedifferentiated subtype, high grade of malignancy, extracompartmental tumor, presence of regional LNM, presence of local recurrence, large tumor size, and whom were married were found to be more likely to have PM. These clinical characteristics are risk factors for developing PM in CHS patients. Our most interesting finding was a statistically significant association in the presence of PM in married patients compared to unmarried patients. The most likely reason for this was that increased social support and encouragement from their spouses resulted in early detection when pulmonary symptoms first manifested. Compared to unmarried patients, married patients also had better treatment adherence and more regular follow-ups \[[@b20-medscimonit-25-10136]\]. As such, married patients were more likely to be diagnosed with PM. The benefit of marital status on survival of cancer patients had been well studied \[[@b21-medscimonit-25-10136]--[@b26-medscimonit-25-10136]\]. These studies suggested that marital status was a protective factor for survival and that married patients had significant survival benefits when compared to unmarried patients. Additionally, marital status was also found to be an independent prognostic factor for chondrosarcoma patients in Gao's study \[[@b27-medscimonit-25-10136]\], who found that married patients were associated with a better prognosis than unmarried patients. In the tumor stage subgroup analysis, however, marital status was not found to be a significant prognostic factor of survival in chondrosarcoma with distant stage, congruent with the results from our study. The small numbers of unmarried patients (only 19 with PM) in our study may have limited the ability to determine a reliable statistically significant difference in survival between married and unmarried patients. As such, the benefit of marriage in CHS patients with PM still needs further investigating in future studies.

Thorkildsen et al. and Angelini et al. stated that histological grade was correlated with the likelihood of local recurrence and distant metastasis rate \[[@b6-medscimonit-25-10136],[@b28-medscimonit-25-10136]\]. Regardless, there was no significant impact of histologic grade on OS in PM patients \[[@b29-medscimonit-25-10136]\]. We found that PM was more frequent with high-grade tumors than with low-grade tumors. Our study determined that a high-grade tumor was a high-risk factor for developing PM in our study, which is in accordance with previous studies \[[@b16-medscimonit-25-10136],[@b30-medscimonit-25-10136],[@b31-medscimonit-25-10136]\]. Among all histologic subtypes, the dedifferentiated subtype had the highest PM rate, with a statistically significant difference. The dedifferentiated subtype had a high metastatic rate of 65%, but was stable after 2-year follow-up \[[@b6-medscimonit-25-10136]\]. Malchenko et al. revealed that pulmonary metastases developed within a few months of diagnosis in 90% of dedifferentiated subtype patients. The high rate of dedifferentiated chondrosarcoma metastases is related to expression of a set of "multifunctional" genes, which might explain this phenomenon \[[@b32-medscimonit-25-10136]\]. In our study, we found that patients with extracompartmental tumors have a higher risk of developing PM than those with intracompartmental tumor. One possible explanations for this is that extracompartmental tumors in CHS may be more aggressive, often presenting in patients who have had inadequate surgical margins \[[@b33-medscimonit-25-10136]\]. Additionally, neurovascular bundles are located extracompartmentally; thus, when a tumor invades them, it can cause hematogenous metastasis. Identification of the aforementioned high-risk clinical characteristics can help physicians in paying more attention to those with high PM risk and better evaluate the possibility of high PM risk. The 1-year and 3-year disease-free survival rates in CHS patients with PM were 36% and 0%, respectively \[[@b29-medscimonit-25-10136]\]. Based on the number of new pulmonary metastatic events per patient-year in each grade of sarcomas, Cipriano et al. proposed that pulmonary screening be performed as follows: annually until 5 years for low grade sarcomas; every 3 months for 2 years, every 6 months from 2 to 5 years, then annually from 5 to 10 years \[[@b13-medscimonit-25-10136]\]. Computed tomography (CT) of the chest had been proven to be more sensitive than positron emission tomography (PET) in detecting pulmonary metastasis from bone sarcomas \[[@b34-medscimonit-25-10136]\]. Hence, we propose that patients with a high risk of PM should receive a chest radiograph, and CT of the chest needs to be performed every 3--6 months for 5 years, then annually from 5 to 10 years.

Our findings on prognostic factors for CHS patients are consistent with previous studies stating that male sex, older age, high-grade tumor, tumor size, dedifferentiated subtype, presence of PM, presence of local recurrence, and resection or amputation are independent prognostic factors \[[@b3-medscimonit-25-10136],[@b4-medscimonit-25-10136],[@b6-medscimonit-25-10136],[@b8-medscimonit-25-10136],[@b10-medscimonit-25-10136],[@b11-medscimonit-25-10136],[@b17-medscimonit-25-10136],[@b30-medscimonit-25-10136],[@b31-medscimonit-25-10136],[@b35-medscimonit-25-10136],[@b36-medscimonit-25-10136]\]. Chemotherapy and radiation therapy were still not able to improve the prognosis of CHS patients \[[@b1-medscimonit-25-10136]\]. Our study showed that both chemotherapy and radiation were associated with poor prognosis in univariate analysis. Prognostic factors of CHS patients with PM development at initial diagnosis were found to include older age, CCC subtype, and large tumor size. Resection of the primary tumor tended to be another prognostic factor that could prolong OS and CSS in PM patients. This finding is congruent with a study by Song, which suggested that resection of the primary tumor was associated with improved survival for patients with metastatic chondrosarcoma at diagnosis \[[@b37-medscimonit-25-10136]\]. Furthermore, pulmonary metastasectomy has proven to be effective to prolong survival among patients with pulmonary metastasis \[[@b14-medscimonit-25-10136],[@b38-medscimonit-25-10136],[@b39-medscimonit-25-10136]\]. Information about pulmonary metastasectomy was not included in this study. Regarding age at diagnosis, we determined that older age (\>67 years old) was one of the independent prognostic factors resulting in a worse prognosis for CHS patients with PM. This result was similar to that of a recent study, which showed that older age was significantly negatively correlated with OS and CSS in patients with metastatic CHS. For each additional 1-year increase in the age of diagnosis with a reference of 60 years (mean age at diagnosis), the increase in the risk of worse OS and CSS were 1.019 and 1.015, respectively \[[@b37-medscimonit-25-10136]\]. The presence of comorbidities and worse performance status in older patients can be reasons for a poor prognosis in CHS patients with PM. As mentioned before, the prognosis in patients with clear cell chondrosarcoma tended to be worse than for patients with other chondrosarcomas. CCC is a rare, low-grade, malignant sarcoma with potential to PM. Donati et al. stated that serum alkaline phosphatase levels are often elevated at diagnosis and may provide a useful tumor marker. Once patients are diagnosed with clear cell subtype, they should undergo tumor resection with wide margin and mandatory long-term follow-up \[[@b40-medscimonit-25-10136]\]. In our study, large tumor size was the homogeneous risk factor for the incidence and prognosis of CHS patients with PM. In univariate analysis, medium and large tumor size were associated with an increase in the risk for having PM, whereas only large tumor size group had a significant association with a high risk of developing PM in multivariate analysis. A possible explanation of this is that a larger tumor size often needs time for tumor growth, increasing the likelihood of metastasis. This highlights the significance of early detection for asymptomatic CHS patients. In survival analysis, large tumor size was associated with a nearly 5-fold increase of the hazard ratio in both OS and CSS. This results in a worse prognosis for patients with large tumor size in both OS and CSS. Our findings were also consistent with recent studies \[[@b16-medscimonit-25-10136],[@b41-medscimonit-25-10136]\] that concluded that increasing tumor size was associated with increased of high risk of distant metastasis and mortality. Based on these prognostic factors, physicians can more accurately estimate the prognosis of PM patients. Resection of the primary tumor and pulmonary metastasectomy are recommended to manage PM development.

Potential limitations of our study include an underestimated PM incidence due to the lack of records for asymptomatic PM patients in the SEER database. Secondly, surgical margin status, pathologic fracture, and pulmonary metastasectomy were shown to be independent prognostic factors in CHS patients in previous studies \[[@b14-medscimonit-25-10136],[@b31-medscimonit-25-10136],[@b38-medscimonit-25-10136],[@b39-medscimonit-25-10136],[@b42-medscimonit-25-10136]\]. Due to insufficient information about these clinical variables in SEER, we were unable to investigate the association between these factors and PM patients. Finally, our study is retrospective and, as such, selection bias and missing data are inevitable; thus, more prospective studies are needed to further confirm the results.

Conclusions
===========

Based on our retrospective analysis of the SEER database, our study demonstrated risk factors for PM development in CHS patients included: having a dedifferentiated subtype, a high grade of malignancy, extracompartmental tumor, presence of regional LNM, presence of local recurrence, large tumor size (\>15 cm), and being married. It was also demonstrated that prognostic factors for CHS patients with PM included older age (\>67 years old), CCC subtype, and large tumor size (\>15 cm). Additionally, resection of the primary tumor tended to be correlated with a better prognosis. The recognition of these risk factors can potentially be used for clinical surveillance through improving the early detection of PM in CHS patients and in counseling patients regarding the possibility of developing PM. The discovery of prognostic factors can help physicians in making a more accurate prognostic estimation and can be used to design a personized treatment plan for patients with PM.
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![The graphs define the optimal cutoff values of age of diagnosis and tumor size using X-tile analysis. The X-tile analysis of the training cohort is demonstrated with the "lock" symbol indicating that optimal cutoff values of age of diagnosis and tumor size have been identified, respectively (**1A, 2A**). A histogram (**1B, 2B**) and survival analysis were developed based on these cutoff values (**1C, 2C**). For age at diagnosis, optimal cutoff values were identified as 67 years old based on overall survival. For tumor size, optimal cutoff values were identified as 8.6 cm and 15 cm based on overall survival.](medscimonit-25-10136-g002){#f2-medscimonit-25-10136}

![The overall survival curve of chondrosarcoma patients stratified by the presence of pulmonary metastasis.](medscimonit-25-10136-g003){#f3-medscimonit-25-10136}

![The overall survival (OS) and cancer-specific survival (CSS) curve of pulmonary metastasis patients stratified by primary surgery site.](medscimonit-25-10136-g004){#f4-medscimonit-25-10136}

![The homogeneous and heterogeneous risk factors for the incidence and prognosis of pulmonary metastasis patients in chondrosarcoma. The left circle was risk factors for developing pulmonary metastasis. The right circle was prognostic factors for PM patients' OS and CSS. The intersection of 2 circles represent the homogeneous risk factor including large tumor size. OS -- overall survival; CSS -- cancer-specific survival; LNM -- lymph nodes metastasis.](medscimonit-25-10136-g005){#f5-medscimonit-25-10136}

###### 

Baseline of the demographic and related clinical characteristics for patients diagnosed with chondrosarcoma.

  Characteristics                   With PM   Without PM   Entire cohort   χ^2^     P                            
  --------------------------------- --------- ------------ --------------- -------- ----- ------- -------------- ---------
  Sex                                                                                             χ^2^=1.086     0.297
   Female                           26        5.9%         417             94.1%    443   43.7%                  
   Male                             43        7.5%         528             92.5%    571   56.3%                  
  Age (52.68±17.64) range (4--95)                                                                 χ^2^=2.101     0.147
   ≤67                              50        6.2%         754             93.8%    804   79.3%                  
   \>67                             19        9.0%         191             91.0%    210   20.7%                  
  Race                                                                                            χ^2^=1.234     0.745
   White                            60        6.9%         812             93.1%    872   86.0%                  
   Black                            6         7.9%         70              92.1%    76    7.5%                   
   Other                            2         3.6%         54              96.4%    56    5.5%                   
   Unknown                          1         10.0%        9               90.0%    10    1.0%                   
  Insurance status                                                                                χ^2^=5.258     0.072
   Uninsured                        5         15.2%        28              84.8%    33    3.3%                   
   Insured                          64        6.7%         895             93.3%    959   94.6%                  
   Unknown                          0         0.0%         22              100.0%   22    2.2%                   
  Marital status                                                                                  χ^2^=9.640     0.008
   Unmarried                        19        4.7%         385             95.3%    404   39.8%                  
   Married                          49        9.0%         497             91.0%    546   53.8%                  
   Unknown                          1         1.6%         63              98.4%    64    6.3%                   
  Primary site                                                                                    χ^2^=1.739     0.628
   Extremities                      37        6.7%         512             93.3%    549   54.1%                  
   Spine                            4         7.0%         53              93.0%    57    5.6%                   
   Thoracic cage                    11        5.3%         198             94.7%    209   20.6%                  
   Others                           17        8.5%         182             91.5%    199   19.6%                  
  Histologic subtype                                                                              χ^2^=49.181    \<0.001
   Conventional                     39        4.7%         791             95.3%    830   81.9%                  
   Myxoid                           3         6.8%         41              93.2%    44    4.3%                   
   Mesenchymal                      1         9.1%         10              90.9%    11    1.1%                   
   Clear cell                       1         5.6%         17              94.4%    18    1.8%                   
   Dedifferentiated                 25        22.5%        86              77.5%    111   10.9%                  
  Grade                                                                                           χ^2^=51.947    \<0.001
   Low grade                        21        3.1%         666             96.9%    687   67.8%                  
   High grade                       36        16.9%        177             83.1%    213   21.0%                  
   Unknown                          12        10.5%        102             89.5%    114   11.2%                  
  Enneking staging                                                                                χ^2^=20.941    \<0.001
   A                                7         2.6%         260             97.4%    267   26.3%                  
   B                                38        11.8%        284             88.2%    322   31.8%                  
   Unknown                          24        5.6%         401             94.4%    425   41.9%                  
  Regional lymph nodes mets                                                                       χ^2^=44.828    \<0.001
   No                               57        5.8%         919             94.2%    976   96.3%                  
   Yes                              6         46.2%        7               53.8%    13    1.3%                   
   Unknown                          6         24.0%        19              76.0%    25    2.5%                   
  Local recurrence                                                                                χ^2^=87.909    \<0.001
   No                               59        5.9%         940             94.1%    999   98.5%                  
   Yes                              9         64.3%        5               35.7%    14    1.4%                   
   Unknown                          1         100.0%       0               0.0%     1     0.1%                   
  Tumor size                                                                                      χ^2^=32.863    \<0.001
   ≤8.6 cm                          18        3.2%         550             96.8%    568   56.0%                  
   \>8.6--15 cm                     26        10.9%        212             89.1%    238   23.5%                  
   \>15 cm                          16        15.1%        90              84.9%    106   10.5%                  
   Unknown                          4         3.9%         98              96.1%    102   10.1%                  
  Primary tumor surgery                                                                           χ^2^=98.059    \<0.001
   No                               34        27.4%        90              72.6%    124   12.2%                  
   Destruction                      0         0.0%         6               100.0%   6     0.6%                   
   Resection                        26        3.4%         731             96.6%    757   74.7%                  
   Amputation                       9         7.8%         107             92.2%    116   11.4%                  
   Surgery, NOS                     0         0.0%         11              100.0%   11    1.1%                   
  Regional lymph nodes removed                                                                    χ^2^=2.579     0.108
   No                               68        7.1%         887             92.9%    955   94.2%                  
   Yes                              1         1.7%         58              98.3%    59    5.8%                   
  Chemotherapy                                                                                    χ^2^=119.422   \<0.001
   None/unknown                     37        4.0%         882             96.0%    919   90.6%                  
   Yes                              32        33.7%        63              66.3%    95    9.4%                   
  Radiation                                                                                       χ^2^=24.117    \<0.001
   None/unknown                     48        5.4%         845             94.6%    893   88.1%                  
   Yes                              21        17.4%        100             82.6%    121   11.9%                  
  Radiation sequence with surgery                                                                 χ^2^=1.772     0.412
   None                             61        6.5%         871             93.5%    932   91.9%                  
   Prior                            2         14.3%        12              85.7%    14    1.4%                   
   After                            6         8.8%         62              91.2%    68    6.7%                   

mets -- metastasis.

###### 

Univariate and multivariate logistic regression for analyzing the demographic and related clinical characteristics for chondrosarcoma patients with pulmonary metastasis at diagnosis.

  Characteristics             With PM   Entire cohort   Incidence   Univariate analysis   Multivariate analysis                                      
  --------------------------- --------- --------------- ----------- --------------------- ----------------------- --------- -------- --------------- ---------
  Sex                                                                                                                                NI              
   Female                     26        443             5.9%        R                                                                                
   Male                       43        571             7.5%        1.306                 0.789--2.161            0.299                              
  Age                                                                                                                                                
   ≥67                        50        804             6.2%        R                                                                NI              
   \>67                       19        210             9.0%        1.500                 0.864--2.604            0.150                              
  Race                                                                                                                               NI              
   White                      60        872             6.9%        R                                                                                
   Black                      6         76              7.9%        1.160                 0.484--2.780            0.739                              
   Other                      2         56              3.6%        0.501                 0.119--2.106            0.346                              
   Unknown                    1         10              10.0%       NA                    NA                      NA                                 
  Insurance status                                                                                                                   NI              
   Uninsured                  5         33              15.2%       R                                                                                
   Insured                    64        959             6.7%        0.400                 0.150--1.072            0.069                              
   Unknown                    0         22              0.0%        NA                    NA                      NA                                 
  Marital status                                                                                                                                     
   Unmarried                  19        404             4.7%        R                                                       R                        
   Married                    49        546             9.0%        1.998                 1.157--3.449            0.013     2.072    1.115--3.853    0.021
   Unknown                    1         64              1.6%        NA                    NA                      NA        NA       NA              NA
  Primary site                                                                                                                                       
   Extremities                37        549             6.7%        R                                                                NI              
   Spine                      4         57              7.0%        1.044                 0.358--3.044            0.937                              
   Thoracic cage              11        209             5.3%        0.769                 0.385--1.537            0.457                              
   Others                     17        199             8.5%        1.293                 0.710--2.352            0.401                              
  Histologic subtype                                                                                                                                 
   Conventional               39        830             4.7%        R                                                       R                        
   Myxoid                     3         44              6.8%        1.484                 0.440--5.004            0.524     0.724    0.168--3.119    0.665
   Mesenchymal                1         11              9.1%        2.028                 0.253--16.245           0.505     1.065    0.124--9.150    0.954
   Clear cell                 1         18              5.6%        1.193                 0.155--9.196            0.865     1.144    0.137--9.519    0.901
   Dedifferentiated           25        111             22.5%       5.896                 3.404--10.212           \<0.001   2.207    1.058--4.603    0.035
  Grade                                                                                                                                              
   Low grade                  21        687             3.1%        R                                                       R                        
   High grade                 36        213             16.9%       6.450                 3.673--11.328           \<0.001   2.946    1.415--6.136    0.004
   Unknown                    12        114             10.5%       NA                    NA                      NA        NA       NA              NA
  Enneking staging                                                                                                                                   
   A                          7         267             2.6%        R                                                                                
   B                          38        322             11.8%       4.970                 2.181--11.324           \<0.001   2.783    1.149--6.743    0.023
   Unknown                    24        425             5.6%        NA                    NA                      NA        NA       NA              NA
  Regional lymph nodes mets                                                                                                                          
   No                         57        976             5.8%        R                                                       R                        
   Yes                        6         13              46.2%       13.820                4.497--42.472           \<0.001   7.727    2.117--28.210   0.002
   Unknown                    6         25              24.0%       NA                    NA                      NA                                 
  Local recurrence                                                                                                                                   
   No                         59        999             5.9%        R                                                       R                        
   Yes                        9         14              64.3%       28.678                9.316--88.283           \<0.001   22.699   5.558--92.696   \<0.001
   Unknown                    1         1               100.0%      NA                    NA                      NA        NA       NA              NA
  Tumor size                                                                                                                                         
   ≤8.6 cm                    18        568             3.2%        R                                                       R                        
   \>8.6--15 cm               26        238             10.9%       2.581                 1.394--4.778            0.003     1.491    0.742--2.994    0.262
   \>15 cm                    16        106             15.1%       4.267                 2.182--8.342            \<0.001   2.259    1.044--4.884    0.038
   Unknown                    4         102             3.9%        NA                    NA                      NA        NA       NA              NA

R -- reference; OR -- odds ratio; CI -- confidence interval; NA -- not applicable; NI -- not included; mets -- metastasis.

###### 

Univariate and multivariate Cox regression for analyzing prognostic factors for chondrosarcoma patients (diagnosed 2010--2016).

  Characteristics                   Median OS      Univariate analysis   Multivariate analysis                                    
  --------------------------------- -------------- --------------------- ----------------------- --------- ------- -------------- ---------
  Sex                                                                                                                             
   Female                           29 (1--83)     R                                                       R                      
   Male                             30 (1--83)     1.356                 1.019--1.804            0.037     1.642   1.216--2.216   0.001
  Age                                                                                                                             
   ≤67                              31 (1--83)     R                                                       R                      
   \>67                             18 (1--83)     3.650                 2.763--4.821            \<0.001   3.115   2.266--4.281   \<0.001
  Race                                                                                                             NI             
   White                            30 (1--83)     R                                                                              
   Black                            30 (1--82)     0.653                 0.346--1.234            0.189                            
   Others                           24 (1--82)     0.633                 0.297--1.346            0.235                            
   Unknown                          NA             NA                    NA                      NA                               
  Insurance status                                                                                                 NI             
   Uninsured                        27 (1--79)     R                                                                              
   Insured                          29 (1--83)     0.705                 0.361--1.375            0.305                            
   Unknown                          NA             NA                    NA                      NA                               
  Marital status                                                                                                   NI             
   Unmarried                        29 (1--83)     R                                                                              
   Married                          29 (1--83)     0.972                 0.730--1.294            0.845                            
   Unknown                          NA             NA                    NA                      NA                               
  Primary site                                                                                                                    
   Extremities                      28 (1--83)     R                                                       R                      
   Spine                            27 (2--83)     0.987                 0.531--1.836            0.967     1.625   0.837--3.152   0.151
   Thoracic cage                    36 (1--83)     0.684                 0.461--1.016            0.060     0.906   0.582--1.410   0.662
   Others                           26 (1--82)     1.421                 1.025--1.971            0.035     1.368   0.945--1.980   0.097
  Histologic subtype                                                                                                              
   Conventional                     33 (1--83)     R                                                       R                      
   Myxoid                           20.5 (1--75)   1.818                 0.953--3.469            0.070     1.571   0.784--3.150   0.203
   Mesenchymal                      25 (4--71)     2.172                 0.690--6.832            0.185     0.688   0.192--2.469   0.566
   Clear cell                       28.5 (1--67)   0.476                 0.066--3.407            0.460     0.761   0.103--5.623   0.789
   Dedifferentiated                 9 (1--68)      8.546                 6.332--11.534           \<0.001   4.199   2.694--6.546   \<0.001
  Grade                                                                                                                           
   Low grade                        35 (1--83)     R                                                       R                      
   High grade                       16 (1--82)     5.483                 4.031--7.460            \<0.001   1.594   1.046--2.428   0.030
   Unknown                          NA             NA                    NA                      NA        NA      NA             NA
  Enneking staging                                                                                                                
   A                                34 (1--83)     R                                                       R                      
   B                                29 (1--83)     3.747                 2.475--5.671            \<0.001   1.721   1.107--2.676   0.016
   Unknown                          NA             NA                    NA                      NA        NA      NA             NA
  Regional lymph nodes mets                                                                                                       
   No                               30 (1--83)     R                                                       R                      
   Yes                              8 (1--70)      3.753                 1.663--8.468            0.001     1.010   0.420--2.431   0.982
   Unknown                          NA             NA                    NA                      NA        NA      NA             NA
  Pulmonary metastasis                                                                                                            
   No                               31 (1--83)     R                                                       R                      
   Yes                              7 (1--82)      10.672                7.736--14.722           \<0.001   3.771   2.472--5.751   \<0.001
  Local recurrence                                                                                                                
   No                               30 (1--83)     R                                                       R                      
   Yes                              6.5 (1--31)    12.368                6.804--22.480           \<0.001   3.030   1.511--6.077   0.002
   Unknown                          NA             NA                    NA                      NA        NA      NA             NA
  Tumor size                                                                                                                      
   ≤8.6 cm                          32 (1--83)     R                                                       R                      
   \>8.6--15 cm                     24 (1--83)     2.603                 1.851--3.659            \<0.001   1.163   0.794--1.703   0.438
   \>15 cm                          16 (1--80)     4.743                 3.262--6.896            \<0.001   2.009   1.327--3.040   0.001
   Unknown                          NA             NA                    NA                      NA        NA      NA             NA
  Primary tumor surgery                                                                                                           
   No                               13.5 (1--82)   R                                                       R                      
   Destruction                      30 (5--77)     NA                    NA                      0.930     NA      NA             NA
   Resection                        33 (1--83)     0.173                 0.126--0.236            \<0.001   0.360   0.229--0.565   \<0.001
   Amputation                       21.5 (1--83)   0.444                 0.293--0.672            \<0.001   0.540   0.315--0.928   0.026
   Surgery, NOS                     45 (7--75)     0.103                 0.014--0.741            0.024     0.184   0.024--1.424   0.105
  Regional lymph nodes removed                                                                                     NI             
   No                               29 (1--83)     R                                                                              
   Yes                              28 (1--81)     1.423                 0.854--2.371            0.175                            
  Chemotherapy                                                                                                                    
   None/unknown                     31 (1--83)     R                                                       R                      
   Yes                              13 (1--74)     5.181                 3.791--7.082            \<0.001   1.347   0.889--2.041   0.159
  Radiation                                                                                                                       
   None/unknown                     31 (1--83)     R                                                       R                      
   Yes                              19 (1--82)     3.288                 2.404--4.496            \<0.001   1.104   0.649--1.879   0.714
  Radiation sequence with surgery                                                                                                 
   None                             30 (1--83)     R                                                       R                      
   Prior                            36 (3--76)     1.630                 0.605--4.392            0.334     0.628   0.190--2.076   0.446
   After                            21.5 (2--80)   1.969                 1.274--3.044            0.002     1.480   0.724--3.026   0.283

R -- reference; HR -- hazard ratio; CI -- confidence interval; NA -- not applicable; NI -- not included; mets -- metastasis*;* OS -- overall survival.

###### 

Univariate and multivariate Cox regression for analyzing overall survival among chondrosarcoma patients with pulmonary metastasis (diagnosed 2010--2016).

  Characteristics                   Median OS      Univariate analysis   Multivariate analysis                                    
  --------------------------------- -------------- --------------------- ----------------------- ------- -------- --------------- -------
  Sex                                                                                                             NI              
   Female                           8 (1--82)      R                                                                              
   Male                             7 (1--70)      1.122                 0.639--1.969            0.689                            
  Age                                                                                                                             
   ≤67                              8 (1--82)      R                                                     R                        
   \>67                             3 (1--59)      2.364                 1.305--4.281            0.005   2.668    1.371--5.192    0.004
  Race                                                                                                            NI              
   White                            7.5 (1--82)    R                                                                              
   Black                            8.5 (1--15)    0.838                 0.258--2.719            0.768                            
   Other                            4 (3--5)       1.433                 0.193--10.652           0.725                            
   Unknown                          NA             NA                    NA                      NA                               
  Insurance status                                                                                                NI              
   Uninsured                        7 (1--8)       R                                                                              
   Insured                          7.5 (1--82)    0.812                 0.247--2.671            0.732                            
  Marital status                                                                                                  NI              
   Unmarried                        7 (1--47)      R                                                                              
   Married                          8 (1--82)      0.677                 0.377--1.214            0.191                            
   Unknown                          NA             NA                    NA                      NA                               
  Primary site                                                                                                    NI              
  Extremities                       6 (1--47)      R                                                                              
   Spine                            7.5 (3--11)    0.365                 0.049--2.692            0.323                            
   Thoracic cage                    3 (1--70)      0.741                 0.342--1.604            0.446                            
   Others                           8 (1--82)      0.657                 0.336--1.285            0.220                            
  Histologic subtype                                                                                                              
   Conventional                     7 (1--82)      R                                                     R                        
   Myxoid                           10 (9--28)     0.743                 0.175--3.148            0.687   1.069    0.223--5.111    0.934
   Mesenchymal                      47.000         0.474                 0.063--3.542            0.467   0.085    0.018--1.294    0.085
   Clear cell                       1.000          10.437                1.275--85.470           0.029   10.971   1.216--98.942   0.033
   Dedifferentiated                 7 (1--21)      1.672                 0.907--3.081            0.099   1.890    0.977--3.655    0.059
  Grade                                                                                                           NI              
   Low grade                        7 (1--59)      R                                                                              
   High grade                       7 (1--82)      0.777                 0.420--1.437            0.422                            
   Unknown                          NA             NA                    NA                      NA                               
  Enneking staging                                                                                                NI              
   A                                7 (1--30)      R                                                                              
   B                                8 (1--82)      0.818                 0.359--1.864            0.633                            
   Unknown                          NA             NA                    NA                      NA                               
  Regional lymph nodes mets                                                                                       NI              
   No                               8 (1--82)      R                                                                              
   Yes                              7.5 (1--28)    1.251                 0.492--3.183            0.638                            
   Unknown                          NA             NA                    NA                      NA                               
  Local recurrence                                                                                                NI              
   No                               7 (1--82)      R                                                                              
   Yes                              5 (1--13)      1.676                 0.737--3.811            0.218                            
   Unknown                          NA             NA                    NA                      NA                               
  Tumor size                                                                                                                      
   ≤8.6 cm                          8.5 (1--82)    R                                                                              
   \>8.6--15 cm                     7.5 (1--70)    1.232                 0.615--2.468            0.555            0.917--4.297    0.082
   \>15 cm                          3.5 (1--47)    2.331                 1.110--4.895            0.025            1.857--11.462   0.001
   Unknown                          NA             NA                    NA                      NA               NA              NA
  Primary tumor surgery                                                                                                           
   No                               7 (1--59)      R                                                                              
   Resection                        10.5 (1--82)   0.507                 0.274--0.937            0.030            0.263--1.075    0.079
   Amputation                       4 (2--30)      1.278                 0.580--2.817            0.542            0.316--1.767    0.506
  Regional lymph nodes removed                                                                                    NI              
   No                               7.5 (1--82)    R                                                                              
   Yes                              3.000          3.825                 0.507--28.859           0.193                            
  Chemotherapy                                                                                           NI                       
   None/unknown                     5 (1--82)      R                                                                              
   Yes                              9.5 (1--47)    0.632                 0.363--1.101            0.106                            
  Radiation                                                                                              NI                       
   None/unknown                     7 (1--82)      R                                                                              
   Yes                              8 (1--47)      0.870                 0.476--1.588            0.650                            
  Radiation sequence with surgery                                                                0.560   NI                       
   None                             7 (1--82)      R                                                                              
   Prior                            7 (4--10)      0.852                 0.116--6.232            0.875                            
   After                            10.5 (6--28)   0.528                 0.164--1.701            0.284                            

R -- reference; HR -- hazard ratio; CI -- confidence interval; NA -- not applicable; NI -- not included; mets -- metastasis*,* OS -- overall survival.

###### 

Univariate and multivariate Cox regression for analyzing cancer-specific survival among chondrosarcoma patients with pulmonary metastasis (diagnosed 2010--2016).

  Characteristics                   Median CSS     Univariate analysis   Multivariate analysis                                   
  --------------------------------- -------------- --------------------- ----------------------- ------- ------- --------------- -------
  Sex                                                                                                                            
   Female                           8 (1--82)      R                                                                             
   Male                             7 (1--70)      1.108                 0.631--1.945            0.720                           
  Age                                                                                                                            
   ≤67                              8 (1--82)      R                                                     R                       
   \>67                             3.5 (1--59)    2.229                 1.221--4.070            0.009   2.446   1.250--4.787    0.009
  Race                                                                                                                           
   White                            8 (1--82)      R                                                                             
   Black                            8.5 (1--15)    0.826                 0.255--2.682            0.751                           
   Other                            4 (3--5)       1.496                 0.201--11.141           0.694                           
   Unknown                          NA             NA                    NA                      NA                              
  Insurance status                                                                                                               
   Uninsured                        7 (1--8)       R                                                                             
   Insured                          8 (1--82)      0.828                 0.252--2.723            0.756                           
  Marital status                                                                                                                 
   Unmarried                        7.5 (1--47)    R                                                                             
   Married                          8 (1--82)      0.728                 0.402--1.318            0.295                           
   Unknown                          NA             NA                    NA                      NA                              
  Primary site                                                                                                                   
   Extremities                      6.5 (1--47)    R                                                                             
   Spine                            7.5 (3--11)    0.750                 0.177--3.172            0.696                           
   Thoracic cage                    3 (1--70)      0.755                 0.348--1.641            0.478                           
   Others                           8 (1--82)      0.672                 0.343--1.319            0.248                           
  Histologic subtype                                                                                                             
   Conventional                     7 (1--82)      R                                                     R                       
   Myxoid                           10 (9--28)     0.709                 0.168--2.999            0.641   0.910   0.191--4.339    0.906
   Mesenchymal                      47.000         0.462                 0.062--3.446            0.451   0.148   0.017--1.257    0.080
   Clear cell                       1.000          9.808                 1.201--80.108           0.033   9.633   1.077--86.191   0.043
   Dedifferentiated                 7.5 (1--21)    1.536                 0.832--2.837            0.170   1.676   0.868--3.237    0.124
  Grade                                                                                                                          
   Low grade                        7 (1--59)      R                                                                             
   High grade                       7 (1--82)      0.714                 0.388--1.313            0.278                           
   Unknown                          NA             NA                    NA                      NA                              
  Enneking staging                                                                                                               
   A                                7 (1--30)      R                                                                             
   B                                8 (1--82)      0.823                 0.361--1.876            0.643                           
   Unknown                          NA             NA                    NA                      NA                              
  Regional lymph nodes mets                                                                                                      
   No                               8 (1--82)      R                                                                             
   Yes                              7.5 (1--28)    1.242                 0.488--3.160            0.649                           
   Unknown                          NA             NA                    NA                      NA                              
  Local recurrence                                                                                                               
   No                               7.5 (1--82)    R                                                                             
   Yes                              5 (1--13)      1.681                 0.739--3.823            0.215                           
   Unknown                          NA             NA                    NA                      NA                              
  Tumor size                                                                                                                     
   ≤8.6 cm                          11 (1--82)     R                                                     R                       
   \>8.6--15 cm                     8 (1--70)      1.100                 0.552--2.191            0.786   1.985   0.917--4.297    0.168
   \>15 cm                          3.5 (1--47)    2.173                 1.048--4.507            0.037   4.613   1.857--11.462   0.001
   Unknown                          NA             NA                    NA                      NA      NA      NA              NA
  Primary tumor surgery                                                                                                          
   No                               7 (1--59)      R                                                     R                       
   Resection                        10.5 (1--82)   0.539                 0.295--0.986            0.045   0.532   0.298--1.187    0.140
   Amputation                       5 (3--30)      1.166                 0.508--2.679            0.717   0.701   0.283--1.740    0.444
  Regional lymph nodes removed                                                                                                   
   No                               8 (1--82)      R                                                                             
   Yes                              3.000          4.053                 0.535--30.704           0.176                           
  Chemotherapy                                                                                                                   
   None/unknown                     5 (1--82)      R                                                                             
   Yes                              9.5 (1--47)    0.623                 0.358--1.084            0.094                           
  Radiation                                                                                                                      
   None/unknown                     7 (1--82)      R                                                                             
   Yes                              8 (1--47)      0.949                 0.526--1.714            0.863                           
  Radiation sequence with surgery                                                                                                
   None                             7 (1--82)      R                                                                             
   Prior                            7 (4--10)      0.873                 0.119--6.391            0.894                           
   After                            10.5 (6--28)   0.711                 0.255--1.983            0.514                           

R -- reference; HR -- hazard ratio; CI -- confidence interval; NA -- not applicable; NI -- not included; mets -- metastasis, CSS -- cancer-specific survival.
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